

55 DDKT Munich Cancer Colloquium

31 January 2022
5:30 - 7:00 pm

Please login with your full name: Meeting ID: 830 1946 9370 Kenncode: 68840493
<https://us02web.zoom.us/j/83019469370?pwd=bzFvdkhvOXAvOHIrZ1dpQWowMIBldz09>

DKTK & CCCM & BZKF & SFBs and all interested are welcome

LLA, Faculty, Fellows of the School of Oncology, Physicians, Post-Docs, PhD/MD students
with 2 CME points for physicians (BLÄK)

Focus: Preclinical Models and Young Scientists

**In vivo PDX CRISPR/Cas9 screens identify
BCL2 inhibition as mechanism to overcome
genetically diverse chemo-resistance**

Prof. Irmela Jeremias

Dr. von Haunersches Kinderspital, LMU Klinikum and Department Apoptosis in Hematopoietic Stem Cells, HMGU

Resistance against conventional chemotherapy represents a major challenge in clinical oncology. In PDX mouse models, replicate animals developed genetically diverse resistance mechanisms, but similar dependency on Bcl-2.

Longitudinal Multi-omic Analysis in Allogeneic Stem Cell Transplantation Patients identifies Microbial and Metabolomic Signatures for Acute Graft-vs-Host-Disease

Dr. med. Erik T. Orberg

Klinik und Poliklinik für Innere Medizin III, MRI and Fellow of the DDKT School of Oncology

In this multi-centric study of patients undergoing allogeneic stem-cell transplantation in Munich and Regensburg, we looked beyond bacterial communities at the fungal and viral microbiome integrated with intestinal metabolomics and identified transkingdom signatures and metabolite profiles that were associated with better survival and less graft-versus-host disease; and are proof-of-concept for microbiome-based therapies.

Radioimmunotherapy of lung tumors with Checkpointinhibitors – what is safe?

Dr. rer. nat. Dr. med. Kim M. Kraus

Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, MRI and Fellow of the DDKT School of Oncology

Radioimmunotherapy as a promising treatment option for lung cancer might induce increased lung toxicity depending on the applied dose and volume irradiated. We investigate the potential of dosimomics based analysis to predict the pneumonitis risk prior to therapy.

DKTK news

Prof. Michael Bergwelt

Deptuy Spokesperson DDKT partner site Munich

- Varia

DKTK Munich Cancer Colloquium in 2022: January 31, March 14, July 4, November 21
[9th Munich Cancer Retreat](#) on May 23-24, 2022 / [TeamSite München](#)

Ärztliche Kursleitung:

Prof. Wilko Weichert / Direktor des Institutes für Allgemeine Pathologie und Pathologische Anatomie der TUM
Prof. Michael von Bergwelt / Direktor der Medizinische Klinik und Poliklinik III am LMU Klinikum

Veranstalter:

DKTK Partnerstandort München, Pettenkoferstr. 8a, 80336 München